Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Neurofibromatoses × Imatinib Mesylate × Clear all

Phase

Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10 Leukemia 8 Leukemia, Myeloid, Chronic-Phase 6 Blast Crisis 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Sarcoma 4 Melanoma 4 Gastrointestinal Stromal Tumors 4 Leukemia, Myeloid, Accelerated Phase 3 Sarcoma, Synovial 2 Oligodendroglioma 2 Leukemia, Myeloid, Acute 2 Glioma 2 Central Nervous System Neoplasms 2 Brain Neoplasms 2 Astrocytoma 2 Uterine Neoplasms 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Sarcoma, Endometrial Stromal 1 Sarcoma, Alveolar Soft Part 1 Rhabdomyosarcoma 1 Refractory Desmoplastic Small Round Cell Tumors 1 Prostatic Neoplasms 1 Primary Myelofibrosis 1 Piebaldism 1 Ovarian Neoplasms 1 Neurofibrosarcoma 1 Neurofibromatoses 1 Neurofibroma 1

Interventions

Imatinib Mesylate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01140360 2017-07-02

0908-09

Indiana University

Phase 1/2 Completed

21 enrolled 8 charts

Neurofibroma, Neurofibromatoses

Data powered by HemOnc (CC BY 4.0) Colophon ⚡